Although CN patients produce physiological amounts of G-CSF (granulocyte colony-stimulating factor), their myeloid precursor cells fail to differentiate normally into mature neutrophils; therefore, these patients require long-term treatment with pharmacological dosages of recombinant human G-CSF (rhG-CSF, Filgrastim). This evidence concerns the gene CSF3 and cyclic hematopoiesis.